Targeting angiogenesis in advanced cervical cancer

Targeting angiogenesis in advanced cervical cancer

Blog Article

Hybrid Shorts Patients with advanced stage or recurrent cervical cancer represent a population with limited chemotherapeutic options.More specifically, patients with recurrent disease have a poor salvage rate, with a 5-year survival rate of less than 10%.This year, the first prospective phase III clinical trial exploring the anti-angiogenic agent, bevacizumab, was Hockey Accessories - Home Sharpening - Machines published, meeting its primary endpoint, with a significant improvement in overall survival.

As such, a review of anti-angiogenic therapy in the treatment of this disease is warranted.